Drug intelligence / Profile preview

IX001 TCR-T cells

Development stage: Phase 1
Lead developer: Shanghai Bintie Biotechnology
Modality: TCR-Engineered T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

IX001 TCR-T cells is a T cell receptor engineered T cell therapy that targets KRAS mutations, particularly KRAS G12V. This cellular therapy involves collecting a patient's own T cells, genetically modifying them to express a T cell receptor that recognizes KRAS mutation-derived peptides presented by MHC molecules, and reinfusing them back into the patient to target and destroy cancer cells harboring these mutations. The therapy is administered intravenously and is followed by recombinant human interleukin-2 (IL-2) injection to support T cell growth and persistence.

Other names: IX001 TCR-T injectionIX-001 TCR-T injectionIX 001 TCR-T injection

Targets

KRAS G12V/HLA-A*11:01 (KRAS G12V Mutant Peptide-HLA-A*11:01 Complex)

Beyond the preview

Go deeper on IX001 TCR-T cells.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IX001 TCR-T cells.